Literature DB >> 11369654

Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis.

E Kolomietz1, J Al-Maghrabi, S Brennan, J Karaskova, S Minkin, J Lipton, J A Squire.   

Abstract

BCR/ABL fluorescent in situ hybridization study of chronic myeloid leukemia (CML) and Philadelphia(+) (Ph(+)) acute lymphoid leukemia (ALL) indicated that approximately 9% of patients exhibited an atypical hybridization pattern consistent with a submicroscopic deletion of the 5' region of ABL and the 3' region of the BCR genes on the 9q(+) chromosome. The CML patients with deletions had a shorter survival time and a high relapse rate following bone marrow transplant. Since deletions are associated with both Ph(+) CML and ALL, it seemed probable that other leukemia-associated genomic rearrangements may also have submicroscopic deletions. This hypothesis was confirmed by the detection of deletions of the 3' regions of the CBFB and the MLL genes in AML M4 patients with inv(16) and in patients with ALL and AML associated with MLL gene translocations, respectively. In contrast, analysis of the AML M3 group of patients and AML M2 showed that similar large deletions were not frequently associated with the t(15;17) or t(8;21) translocations. Analysis of sequence data from each of the breakpoint regions suggested that large submicroscopic deletions occur in regions with a high overall density of Alu sequence repeats. These findings are the first to show that the process of deletion formation is not disease specific in leukemia and also implicate that the presence of repetitive DNA in the vicinity of breakpoint regions may facilitate the generation of submicroscopic deletions. Such deletions could lead to the loss of one or more genes, and the associated haploinsufficiency may result in the observed differences in clinical behavior. (Blood. 2001;97:3581-3588)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369654     DOI: 10.1182/blood.v97.11.3581

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

2.  Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics.

Authors:  Lina Shao; Sung-Hae L Kang; Jian Li; Patricia Hixson; Jesalyn Taylor; Svetlana A Yatsenko; Chad A Shaw; Aleksandar Milosavljevic; Chung-Che Chang; Sau Wai Cheung; Ankita Patel
Journal:  J Mol Diagn       Date:  2010-08-19       Impact factor: 5.568

3.  The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.

Authors:  L Shan; L Ambroisine; J Clark; R J Yáñez-Muñoz; G Fisher; S C Kudahetti; J Yang; S Kia; X Mao; A Fletcher; P Flohr; S Edwards; G Attard; J De-Bono; B D Young; C S Foster; V Reuter; H Moller; T D Oliver; D M Berney; P Scardino; J Cuzick; C S Cooper; Y-J Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-02-23       Impact factor: 5.554

4.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Susan Chilton-Macneill; Jane Bayani; Shamini Selvarajah; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

5.  Guidance for fluorescence in situ hybridization testing in hematologic disorders.

Authors:  Daynna J Wolff; Adam Bagg; Linda D Cooley; Gordon W Dewald; Betsy A Hirsch; Peter B Jacky; Kathleen W Rao; P Nagesh Rao
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

6.  Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR/ABL transcripts but missing normal ABL gene.

Authors:  Phan Nguyen Thanh Van; Phan Thi Xinh; Yasuhiko Kano; Katsushi Tokunaga; Yuko Sato
Journal:  Hum Cell       Date:  2005-03       Impact factor: 4.174

7.  Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.

Authors:  Giovanni Cazzaniga; Frederik W van Delft; Luca Lo Nigro; Anthony M Ford; Joannah Score; Ilaria Iacobucci; Elena Mirabile; Mary Taj; Susan M Colman; Andrea Biondi; Mel Greaves
Journal:  Blood       Date:  2011-09-29       Impact factor: 22.113

8.  Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population.

Authors:  Yanmin Zhao; Lizhen Liu; Yingjia Wang; Gongqiang Wu; Xiaoyu Lai; Weijie Cao; Yi Luo; Yamin Tan; Jimin Shi; Wanzhuo Xie; Xiujin Ye; Zhen Cai; Maofang Lin; He Huang
Journal:  Int J Hematol       Date:  2009-04-07       Impact factor: 2.490

9.  Acquired copy number alterations in adult acute myeloid leukemia genomes.

Authors:  Matthew J Walter; Jacqueline E Payton; Rhonda E Ries; William D Shannon; Hrishikesh Deshmukh; Yu Zhao; Jack Baty; Sharon Heath; Peter Westervelt; Mark A Watson; Michael H Tomasson; Rakesh Nagarajan; Brian P O'Gara; Clara D Bloomfield; Krzysztof Mrózek; Rebecca R Selzer; Todd A Richmond; Jacob Kitzman; Joel Geoghegan; Peggy S Eis; Rachel Maupin; Robert S Fulton; Michael McLellan; Richard K Wilson; Elaine R Mardis; Daniel C Link; Timothy A Graubert; John F DiPersio; Timothy J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

10.  Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines.

Authors:  An De Weer; Bruce Poppe; Sarah Vergult; Pieter Van Vlierberghe; Marjan Petrick; Robrecht De Bock; Yves Benoit; Lucien Noens; Anne De Paepe; Nadine Van Roy; Björn Menten; Frank Speleman
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.